# US 2024/0390322 A1 · Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0390322 A1
- Document ID: US20240390322A1
- Status: Published application
- Kind: A1
- Application number: 18/790,708
- Filed: 2024-07-31
- Published: 2024-11-28
- Earliest claimed: 2021-08-06
- Assignees: Transcend Therapeutics, Inc.
- Applicants: Transcend Therapeutics, Inc.
- Inventors: Blake MANDELL; Martin STOGNIEW; Jennifer Louise SCHMIDT; Markus SEELIG
- Web page: https://patentgrep.com/patent/US20240390322A1

## CPC

- A61K 31/36: Compounds containing methylenedioxyphenyl groups, e.g. sesamin
- A61K 31/343: condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 25/22: Anxiolytics
- A61P 25/24: Antidepressants
- A61K 2300/00: Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention relates to psychoactive medicines including methylone, 2C-B, MBDB, their respective salts, metabolites, isomers, enantiomers, solvates, isotopologues and isotopomers, polymorphs, prodrugs and analogs (2C-series and cathinones); their preparation, formulations, intermediates, routes of administration, dosing and schedule for medical uses for psychiatric and neurological conditions and disorders.

## Claims

### Claim at position 1

-10. (canceled)

### Claim 11

A method of treating and/or preventing a neuropsychiatric illness and/or ameliorating a symptom thereof in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising methylone (3,4-methylenedioxy-N-methylcathinone) or a pharmaceutically acceptable salt thereof, and/or an enantiomer thereof, and/or an isotopologue thereof, and/or an isotopomer thereof, and/or a solvate thereof, and/or a prodrug thereof, and/or a polymorph thereof.

### Claim 12

(canceled)

### Claim 13

(canceled)

### Claim 14 (depends on 11)

The method according to claim 11, wherein the neuropsychiatric illness is selected from a Depressive Disorder, post-traumatic stress disorder (PTSD), acute stress disorder, an Anxiety Disorder and/or Fibromyalgia.

### Claim at position 6

-21. (canceled)

### Claim 22 (depends on 11)

The method according to claim 11, wherein methylone is administered in a dose of 5-250 mg.

### Claim 23 (depends on 11)

The method according to claim 11, wherein methylone is administered in a dose of 50-1,000 mg.

### Claim 24 (depends on 11)

The method according to claim 11, wherein methylone is administered in a dose of 0.08-4 mg/kg. (delete?)

### Claim 25 (depends on 11)

The method according to claim 11, wherein methylone is administered weekly.

### Claim 26 (depends on 11)

The method according to claim 11, wherein methylone is administered more frequently than weekly.

### Claim 27 (depends on 11)

The method according to claim 11, wherein methylone is administered less frequently than weekly.

### Claim 28 (depends on 11)

The method according to claim 11, wherein methylone is administered orally.

### Claim 29 (depends on 11)

The method according to claim 11, wherein the subject is a human.

### Claim 30 (depends on 11)

The method according to claim 11, wherein the neuropsychiatric illness is treatment-resistant.

### Claim 31

(canceled)

### Claim 32 (depends on 11)

The method according to claim 11, wherein the methylone is used in combination with an additional therapy for the neuropsychiatric illness.

### Claim 33

(canceled)

### Claim 34 (depends on 32)

The method according to claim 32, wherein the additional therapy comprises psychotherapy and/or administering one or more additional psychoactive agents to the subject.

### Claim 35 (depends on 34)

The method according to claim 34, wherein the additional psychoactive agents are selected from the group consisting of selective-serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants (TCAs), monoamine oxidase inhibitors (MAOIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), serotonin-norepinephrine-dopamine reuptake inhibitors (SDNRIs), and anxiolytic agents.

### Claim at position 21

-64. (canceled)

### Claim 65

A method of treating and/or preventing a neuropsychiatric illness and/or ameliorating a symptom thereof in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a serotonin-norepinephrine-dopamine reuptake inhibitor and releaser that lacks agonist or antagonist activity at the 5-HT2A and 5-HT2B receptors.

### Claim 66 (depends on 65)

The method according to claim 65, wherein the serotonin-norepinephrine-dopamine reuptake inhibitor and releaser further lacks agonist or antagonist activity at the 168 G-protein coupled receptors (GPCRs) set forth in Table 6.

### Claim 67 (depends on 65)

The method according to claim 65, wherein the neuropsychiatric illness is selected from a Depressive Disorder, post-traumatic stress disorder (PTSD), acute stress disorder, an Anxiety Disorder and/or Fibromyalgia.

### Claim at position 25

-73. (canceled)

### Claim 74 (depends on 65)

The method according to claim 65, wherein the serotonin-norepinephrine-dopamine reuptake inhibitor and releaser has a Ki for 5-HT2A greater than or equal to 8 μM and a Ki for 5-HT2B greater than or equal to 1 μM.

### Claim 75 (depends on 65)

The method according to claim 65, wherein the serotonin-norepinephrine-dopamine reuptake inhibitor and releaser has reuptake inhibition (IC50) of less than or equal to 3 μM at the serotonin transporter (SERT), and less than or equal to 1 μM at the norepinephrine transporter (NET), and less than or equal to 4 μM at the dopamine transporter (DAT); and EC50 values for neurotransmitter release of less than or equal to 2 μM at the SERT, and less than or equal to 1 μM at the NET and less than or equal to 6 μM at the DAT.

### Claim 76 (depends on 75)

The method according to claim 75, wherein the serotonin-norepinephrine-dopamine reuptake inhibitor and releaser has reuptake inhibition (IC50) of less than or equal to 1 μM at the SERT), and less than or equal to 0.5 μM at the NET, and less than or equal to 3 μM at the DAT; and an EC50 value for neurotransmitter release of greater than or equal to 2 μM at the DAT.

### Claim 77 (depends on 66)

The method according claim 66, wherein agonist or antagonist activity is determined using an in vitro β-arrestin based screen and a concentration of 1 μM of the serotonin-norepinephrine-dopamine reuptake inhibitor and releaser, and a threshold for agonist activity is less than 30% and a threshold for antagonist activity is less than 50%.

### Claim 78 (depends on 77)

The method according to claim 77, wherein GPCR agonist or antagonist activity is determined using an in vitro β-arrestin based screen and a concentration of 10 μM of the serotonin-norepinephrine-dopamine reuptake inhibitor and releaser.

### Claim 79 (depends on 65)

The method according claim 65, wherein the serotonin-norepinephrine-dopamine reuptake inhibitor and releaser is non-hallucinogenic and/or non-psychedelic and/or non-dissociative.

### Claim at position 32

-109. (canceled)

### Claim 110

A method of treating a neuropsychiatric illness, and/or ameliorating a symptom thereof in a human subject in need thereof, comprising administering to the subject a pharmaceutical composition comprising methylone (3,4-methylenedioxy-N-methylcathinone) or a pharmaceutically acceptable salt thereof, and/or an enantiomer thereof, and/or an isotopologue thereof, and/or an isotopomer thereof, and/or a solvate thereof, and/or a polymorph thereof, and/or a prodrug thereof in a therapeutically effective amount that results in a plasma Cmax of methylone of 98-994 ng/ml in the subject.

### Claim 111

A method of treating a neuropsychiatric illness, and/or ameliorating a symptom thereof in a human subject in need thereof, comprising administering to the subject a pharmaceutical composition comprising methylone (3,4-methylenedioxy-N-methylcathinone) or a pharmaceutically acceptable salt thereof, and/or an enantiomer thereof, and/or an isotopologue thereof, and/or an isotopomer thereof, and/or a solvate thereof, and/or a polymorph thereof and/or a prodrug thereof in a therapeutically effective amount that results in a plasma AUC0-24 of methylone of 47-10,983 ng·h/mL in the subject.

### Claim 112 (depends on 110)

The method according to claim 110, wherein the neuropsychiatric illness is selected from a Depressive Disorder, post-traumatic stress disorder (PTSD), acute stress disorder, an Anxiety Disorder and/or Fibromyalgia.

### Claim at position 36

-150. (canceled)

### Claim 151 (depends on 65)

The method according to claim 65, wherein the serotonin-norepinephrine-dopamine reuptake inhibitor and releaser increases the length of neurites in the subject.
